Skip to main content

Detail

Thomas Klikovits
Dr. med. univ. Thomas Klikovits, PhD

Department of Surgery (Division of Thoracic Surgery)
Position: Doctor-in-training

ORCID: 0000-0003-1012-0404

Keywords

Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Mesothelioma; Neoplasm Staging; Thoracic Surgery

Selected publications

  1. Klikovits, T. et al., 2018. New insights into the impact of primary lung adenocarcinoma location on metastatic sites and sequence: A multicenter cohort study. Lung Cancer, 126, pp.139-148. Available at: http://dx.doi.org/10.1016/j.lungcan.2018.11.004.
  2. Klikovits, T. et al., 2017. Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma. Scientific Reports, 7(1). Available at: http://dx.doi.org/10.1038/s41598-017-16551-7.
  3. Laszlo, V. et al., 2018. Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo. Clinical Cancer Research, 24(15), pp.3729-3740. Available at: http://dx.doi.org/10.1158/1078-0432.CCR-17-1507.
  4. Lohinai, Z. et al., 2017. KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis. Scientific Reports, 7(1). Available at: http://dx.doi.org/10.1038/srep39721.
  5. Ghanim, B. et al., 2015. Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study. British Journal of Cancer, 112(5), pp.783-792. Available at: http://dx.doi.org/10.1038/bjc.2015.9.